Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Arzneimittel-Forschung|June 15, 1999
Placebo--efficacy and adverse effects in controlled clinical trialsT R Weihrauch, T C Gauler
HNO|December 19, 2012
[Immunotherapy of head and neck cancer. Current developments]P J Schuler, T K Hoffmann, T C Gauler, et al.
British Journal of Cancer|August 15, 2013
Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatmentI Nel, T C Gauler, W E Eberhardt, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2013
Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neckJ B Vermorken, L Licitra, J Stöhlmacher-Williams, et al.
Oncology|March 1, 2013
Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische OnkologieM Knoedler, T C Gauler, V Gruenwald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2014
TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)V Grünwald, U Keilholz, A Boehm, et al.
Cell Death & Disease|March 1, 2014
Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapyM Pogorzelski, S Ting, T C Gauler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 28, 2011
Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)T C Gauler, B Besse, A Mauguen, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2015
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neckJ-P Machiels, P Specenier, J Krauß, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 27, 2011
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancerA Schmittel, M Sebastian, L Fischer von Weikersthal, et al.
Pageof 2